Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quest Diagnostics Snags Thermo Fisher’s Neuro Testing Lab Biz For $740 Mil.

This article was originally published in The Gray Sheet

Executive Summary

Thermo Fisher Scientific is selling two diagnostic services units, including its Athena Diagnostics neurology testing business, for a total of $940 million, the company announced Feb. 24.

You may also be interested in...



Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011

For the first three months of 2011, medical device companies raised $733 million, with venture rounds bringing in $494 million. Two-thirds of the $3.9 billion in M&A activity came from Terumo's monstrous $2.6 billion cash takeover of US blood processing equipment maker CaridianBCT Holding. Buoyed by Opko Health's $105 million follow-on, the FOPO category represented almost half of the first quarter's in vitro diagnostics/research $370 million total. The stand-out IVD acquisition was Danaher's $6.8 billion takeover of publicly traded Beckman Coulter.

Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase

Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.

Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase

Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel